#DIA2017 Day2 – Patient Engagement and Patient Recruitment Solutions In Focus

21 Jun

#DIA2017 Day2 – Patient Engagement and Patient Recruitment Solutions In Focus

by Shweta Mishra

iConnect

We had another busy day at booth # 2513 on day 2 of #DIA2017.

Day 2 started with sessions loaded with discussions on #bigdata, #patientengagement, #patientcentricity and issues with implementing these efforts that the #clinicalresearch industry faces today.

Here are some tweets/quotes and highlights from the industry leaders that will give you an idea about the radical changes being discussed around patient-centricity, patient engagement and patient focussed medicine in the clinical trial industry at the DIA2017.

 

We squeezed out some time from our busy day at the booth to attend to some great discussions. Here are the pics from one of the sessions where Mintu Turakhia @leftbundle, Director of Research/Innovation at Stanford Center for Digitalhealth, Craig Lipset @CraigLipset from Pfizer and Wayne Amchin from FDA discussed Mobile Health & Participatory research

 

Later in the evening, we had a great time at the networking event organized by our iConnect partner WCG @wcgclinical

 

We look forward to meet more innovative folks at booth 2513 and attend some more great sessions on day3 at DIA2017 !

Read Day 1  and Day 3 highlights here.

Bake your own Mobile Research App. No coding. No upfront cost.

Register Now
Shweta Mishra
Shweta Mishra
shweta@trialx.com

Shweta is senior marketing and content manager and also provides research and engagement support for Applied Informatics/TrialX products. She hosts women's health/infertility/reproductive medicine talk series driven by her personal experiences for TrialX CureTalks. A San Jose State University Graduate, she holds dual masters degree in Biochemistry and Nutrition Science, and is passionate about the science behind the diverse life phenomenas. She also holds certifications in Digital Marketing from Hubspot Academy, Protecting Human Research Participants from NIH and in Intellectual Property in Biotechnology from WIPO.

No Comments

Sorry, the comment form is closed at this time.

Shares